In Depth

Redefining ‘druggability’ with multi-modal target ID screening

As drug discovery demands ever closer analysis to ensure quality and validation of drug targets, Dr Benedict Cross looks at how to use a multi-modal approach to explore and identify drug-mimetics in …

Comment And Analysis

“Let’s not wait another 100 years to collaborate” appeals President of The Pistoia Alliance

The breakthroughs in vaccine development that have been achieved in just ten months clearly demonstrate the value of working together across biopharma and how collaboration can produce hugely valuabl…


Foundational science of the future

Traditionally pharma has been focused on developing small molecules and chemicals. Here, David Ferrick gives his view on immunology and cell therapy as a rapidly emerging pillar of science and therap…